Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Australia’s medical device industry is continuing to expand rapidly, and Melbourne serves as the core hub that supports innovation and employment. Melbourne’s medical device industry offers customized career development pathways that accommodate diverse professional backgrounds, for both early-career practitioners and professionals seeking to advance into senior roles. Key Takeaways Understanding the Medical Device Sector The […]

The post Building Your Career in Melbourne’s Growing Medical Device Industry appeared first on Medical News Bulletin.

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Struggling to get your child to eat? Stanford mental health researchers say family therapy could be the key. In an April 2026 paper published by the Journal of the American Academy of Child and Adolescent Psychiatry, a team of experts from Stanford University and John’s Hopkins University announced the results of an early investigation into […]

The post First Evidence-Based ARFID Treatments appeared first on Medical News Bulletin.

In previous articles, I introduced retinal reserve as a framework for understanding the retina’s ability to maintain function despite underlying stress and dysfunction.
If functional decline often precedes visible structural damage, an important clinical question follows: How do we measure retinal reserve before irreversible loss occurs?
While OCT remains foundational, I believe the next frontier of proactive retinal care will combine functional testing with targeted systemic biomarkers (Owsley et al.). Together, these tools may help identify retinal stress before structural disease

The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to an agency press release.
Atacicept-vymj (Trutakna, Vera Therapeutics) is the first approved medication to target both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in immunoglobulin A (IgA) nephropathy.
Approval was based on a prespecified interim analysis of proteinuria endpoints in the ORIGIN 3 clinical trial. In data published in The New England Journal of Medicine in 2025, adults with

As a coauthor of this column for a number of years now, I have covered the topic of disability insurance in the past. As all orthopedists know, in theory at least, disability can happen to any of us, and for physicians and surgeons who need to use their hands and physically examine patients, a long-term disability can be mean financial devastation if not properly protected against through insurance.
While the theory makes sense, of course, I wanted to go beyond theory in this month’s column , coauthor ed by a colleague of mine — Stephanie Pearson, MD, FACOG, an OB / GYN who suffered a long -

Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA granted regenerative medicine advanced therapy designation to EO2002 for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release from Emmecell.
The allogeneic cultured human corneal endothelial cell therapy uses the company’s Magnetic Cell Delivery platform to restore corneal endothelial function by improving the localization and retention of therapeutic cells, the release said. This helps restore function without interventions such as endothelial

Future strategies to improve HPV vaccination rates could include AI, but tailored interventions involving public health messaging may achieve greater uptake.
According to findings from a randomized trial of nearly 1,300 parents, HPV vaccination information from AI chatbots or public health agencies such as CDC increased immediate intent to vaccinate, but only public health messaging maintained its significant impact 45 days later.
“AI chatbots are promising, but they should not be assumed to outperform existing tools simply because they are newer or more interactive,” Neil K. R. Sehgal, ME, MS,

CHICAGO — A noninvasive blood-based test identified cases of endometriosis that were missed by imaging, data at the Endocrine Society annual meeting show.
“One of the greatest challenges with endometriosis is timely diagnosis,” Farideh Bischoff, PhD, chief medical officer of HerAnova Life Sciences, the device’s manufacturer, told Healio. “Today, women are experiencing up to a decade or more delay in getting a confirmatory diagnosis, even though they have clinical symptoms and present with disabilities such as pelvic pain and dysmenorrhea.”
The HerResolve test can “shorten that window and bring

PHILADELPHIA — Menopause is an important time to prioritize women’s cardio-kidney-metabolic health, but questions remain about the impact of estrogen and hormone therapy on progression of heart disease, a speaker reported.
At the Heart in Diabetes CME Conference, Martha Gulati, MD, MS, FACC, FAHA, FASPC, director of the Davis Women’s Heart Center at Houston Methodist DeBakey Heart & Vascular Center, discussed menopause and the importance of improving CV clinical competencies related to menopausal transition.
“These days, so many patients are coming to us asking is it safe to be on

Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by the FDA and the European Medicines Agency, according to officials with Regeneron Pharmaceuticals.
If approved, cemdisiran would be the first small interfering RNA (siRNA) treatment for generalized myasthenia gravis, a chronic autoimmune disorder, and the only therapy to be offered subcutaneously with four doses needed annually, said Tuan Vu, MD, professor of neurology at the University of South Florida Morsani College of Medicine.
“While current therapies have mitigated